Skip to main content

Peer Review reports

From: A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO)

Original Submission
25 Apr 2016 Submitted Original manuscript
30 Sep 2016 Reviewed Reviewer Report - Chang-Hsien Lu
14 Nov 2016 Reviewed Reviewer Report - Virginia Kaklamani
30 Nov 2016 Reviewed Reviewer Report - Ross Graham
31 Jan 2017 Author responded Author comments - Thomas Decker
Resubmission - Version 2
31 Jan 2017 Submitted Manuscript version 2
4 Jul 2017 Author responded Author comments - Thomas Decker
Resubmission - Version 3
4 Jul 2017 Submitted Manuscript version 3
11 Jul 2017 Author responded Author comments - Thomas Decker
Resubmission - Version 4
11 Jul 2017 Submitted Manuscript version 4
17 Jul 2017 Author responded Author comments - Thomas Decker
Resubmission - Version 5
17 Jul 2017 Submitted Manuscript version 5
Publishing
20 Jul 2017 Editorially accepted
25 Jul 2017 Article published 10.1186/s12885-017-3492-1

You can find further information about peer review here.

Back to article page